


Gilead Sciences, Inc. (GILD)


Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0000882095

Gilead Sciences, Inc. GILD; healthcare	
Grade	D/E A B C D E ▼ on the D/E boundary of 371 graded peers percentile 78.9; sampling error 2.5 points; lower is stronger
Rank	293 of 371
Profitability	C percentile 43.4
Solvency	D/E percentile 79.5
Growth and financing	C percentile 53.3
Reliability	0.94 AUC filers with over \$2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over \$2.67B assets total assets \$59.0B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active not computable: short runway, distress
Inputs computable	9 of 14
Graded from	filings received through Feb 24, 2026 227 days before the rescans; latest periodic filing 10-Q received Aug 6, 2026
Last close	\$147.07 2026-10-08; market equity \$182.4B
Price used in grade	None



D/E, the sloth
on the D/E boundary of its sector; letters are fifths of the 371 graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: B from Feb 21, 2024, C from Mar 21, 2024, C/D from Apr 21, 2024

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words


opening of Item 1 of the 10-K received Feb 24, 2026

Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as "Gilead," the "company," "we," "our" or "us") is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in

The fourteen inputs*lower percentile is stronger; equal-weighted sleeves*

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 43.4						
Gross profitability		39.3%	32.2%	33.7	372	2025-12-31
Return on invested capital		not computable	9.3%			latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31
Accruals ratio		(2.6%)	(6.6%)	73.7	811	2025-12-31
Gross margin stability, five years		1.4 pts	2.8 pts	22.7	243	2025-12-31
Solvency, sleeve percentile 79.5						
Twelve-month failure probability		not computable	0.07%			liabilities and a nearby cover-page share count are required at 2026-06-30 one or more required annual facts are missing latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31
Altman Z double-prime		not computable	(0.31)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Net debt to EBITDA		not computable	1.82x			
Interest coverage		not computable	(4.51x)			
Current ratio		1.55x	2.96x	79.5	839	2025-12-31
Growth and financing, sleeve percentile 53.3						
Revenue growth, three-year compound		2.6%	10.0%	65.0	415	2025-12-31
Free cash flow growth, three-year compound		4.3%	10.9%	62.1	96	2025-12-31
Reinvestment rate		(5.1%)	37.1%	71.8	104	2025-12-31
Asset growth, three years		(2.2%)	2.1%	56.9	704	2025-12-31
Net share issuance, one year		(0.3%)	2.5%	10.9	634	2026-02-13

Among 371 peers*healthcare; letters are fifths of this list*



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
288	biote Corp. (BTMD)	77.6	D/E	
289	Protalix BioTherapeutics, Inc. (PLX)	77.8	D/E	
290	Femasys Inc. (FEMY)	78.1	D/E	dilution, short runway
291	X4 Pharmaceuticals, Inc. (XFOR)	78.4	D/E	dilution, fortress balance sheet
292	Milestone Scientific Inc. (MLSS)	78.6	D/E	late filer
293	Gilead Sciences, Inc. (GILD) <	78.9	D/E	
294	C4 Therapeutics, Inc. (CCCC)	79.2	D/E	dilution, fortress balance sheet
295	Whitehawk Therapeutics, Inc. (WHWK)	79.5	D/E	
296	Ironwood Pharmaceuticals Inc. (IRWD)	79.7	D/E	late filer, fortress balance sheet
297	Champions Oncology, Inc. (CSBR)	80.0	D/E	
298	Voyager Therapeutics, Inc. (VYGR)	80.3	D/E	short runway

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	33.6%	8.0%	68
Distance from 52-week high	(5.6%)	(31.4%)	92
EBIT to enterprise value	4.9%	(1.5%)	77
Free cash flow yield	5.2%	(1.0%)	83
Book value to price	0.06	0.28	22
Sales to price	0.16	0.31	36
Composite equity issuance, five years	(21.8%)	20.3%	7
Relative strength against the sector, log excess return	0.08	(0.14)	68

Diagnostics

not in the grade

Measure	Value
Piotroski F-score 8 of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass

Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	64 (10-Q received Aug 6, 2026)
Median daily dollar volume, 63 sessions	\$779.0M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$29.4B	2025-12-31	2026-02-24	10-K	0000882095-26-000006
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$6.2B	2025-12-31	2026-02-24	10-K	0000882095-26-000006
3	assets	us-gaap:Assets	\$59.0B	2025-12-31	2026-02-24	10-K	0000882095-26-000006
4	operating income	us-gaap:OperatingIncomeLoss	\$7.3B	2022-12-31	2025-02-28	10-K	0000882095-25-000006
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$5.9B	2025-12-31	2026-02-28	10-K	0000882095-26-000006
6	income tax	us-gaap:IncomeTaxExpenseBenefit	\$1.2B	2022-12-31	2025-02-28	10-K	0000882095-25-000006
7	total debt	us-gaap:LongTermDebt	\$25.2B	2022-12-31	2024-02-23	10-K	0000882095-24-000007
8	book equity	us-gaap:StockholdersEquity	\$21.2B	2022-12-31	2024-02-23	10-K	0000882095-24-000007
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$5.4B	2022-12-31	2023-02-22	10-K	0000882095-23-000007
10	total debt	us-gaap:LongTermDebt	\$26.7B	2021-12-31	2023-02-22	10-K	0000882095-23-000007
11	book equity	us-gaap:StockholdersEquity	\$21.1B	2021-12-31	2023-02-22	10-K	0000882095-23-000007
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$5.3B	2021-12-31	2023-02-22	10-K	0000882095-23-000007
13	net income	us-gaap:NetIncomeLoss	\$8.5B	2025-12-31	2026-02-24	10-K	0000882095-26-000006
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$10.0B	2025-12-31	2026-02-24	10-K	0000882095-26-000006
15	assets	us-gaap:Assets	\$59.0B	2024-12-31	2026-02-24	10-K	0000882095-26-000006
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$28.8B	2024-12-31	2026-02-24	10-K	0000882095-26-000006
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$6.3B	2024-12-31	2026-02-24	10-K	0000882095-26-000006
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$27.1B	2023-12-31	2026-02-24	10-K	0000882095-26-000006
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$6.5B	2023-12-31	2026-02-24	10-K	0000882095-26-000006
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$27.3B	2022-12-31	2025-02-28	10-K	0000882095-25-000006
21	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$5.7B	2022-12-31	2025-02-28	10-K	0000882095-25-000006
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$27.3B	2021-12-31	2024-02-23	10-K	0000882095-24-000007
23	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	\$6.6B	2021-12-31	2024-02-23	10-K	0000882095-24-000007
24	depreciation amortization	us-gaap:Depreciation	\$323.0M	2022-12-31	2025-02-28	10-K	0000882095-25-000006
25	operating income	us-gaap:OperatingIncomeLoss	\$7.6B	2023-12-31	2026-02-24	10-K	0000882095-26-000006
26	interest expense	us-gaap:InterestExpense	\$944.0M	2023-12-31	2024-02-23	10-K	0000882095-24-000007
27	current assets	us-gaap:AssetsCurrent	\$18.3B	2025-12-31	2026-02-24	10-K	0000882095-26-000006
28	current liabilities	us-gaap:LiabilitiesCurrent	\$11.8B	2025-12-31	2026-02-24	10-K	0000882095-26-000006
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$563.0M	2025-12-31	2026-02-24	10-K	0000882095-26-000006
30	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$10.8B	2024-12-31	2026-02-24	10-K	0000882095-26-000006
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$523.0M	2024-12-31	2026-02-24	10-K	0000882095-26-000006
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$8.0B	2023-12-31	2026-02-24	10-K	0000882095-26-000006
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$585.0M	2023-12-31	2026-02-24	10-K	0000882095-26-000006
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$9.1B	2022-12-31	2025-02-28	10-K	0000882095-25-000006
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$728.0M	2022-12-31	2025-02-28	10-K	0000882095-25-000006
36	depreciation amortization	us-gaap:Depreciation	\$370.0M	2025-12-31	2026-02-24	10-K	0000882095-26-000006
37	operating income	us-gaap:OperatingIncomeLoss	\$10.0B	2025-12-31	2026-02-24	10-K	0000882095-26-000006
38	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$9.8B	2025-12-31	2026-02-24	10-K	0000882095-26-000006
39	income tax	us-gaap:IncomeTaxExpenseBenefit	\$1.3B	2025-12-31	2026-02-24	10-K	0000882095-26-000006
40	current assets	us-gaap:AssetsCurrent	\$19.2B	2024-12-31	2026-02-24	10-K	0000882095-26-000006
41	current liabilities	us-gaap:LiabilitiesCurrent	\$12.0B	2024-12-31	2026-02-24	10-K	0000882095-26-000006
42	assets	us-gaap:Assets	\$62.1B	2023-12-31	2025-02-28	10-K	0000882095-25-000006
43	assets	us-gaap:Assets	\$63.2B	2022-12-31	2024-02-23	10-K	0000882095-24-000007
44	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,241,420,528	2026-02-13	2026-02-24	10-K	0000882095-26-000006
45	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,245,346,062	2025-02-21	2025-02-28	10-K	0000882095-25-000006